Global Restless Legs Syndrome Market 2015-2019 Featuring Boehringer Ingelheim, GlaxoSmithKline, UCB & XenoPort
DUBLIN, June 24, 2015 /PRNewswire/ --
Research and Markets(http://www.researchandmarkets.com/research/646k6k/global_restless) has announced the addition of the "Global Restless Legs Syndrome Market 2015-2019" report to their offering.
The analysts forecast the global RLS market to grow at a CAGR of 11.46% over the period 2014-2019.
This report covers the present scenario and the growth prospects of the global RLS market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of RLS.
The drugs marketed for RLS such as safinamide by Newron Pharmaceuticals appear to reduce the symptoms by novel mechanisms of action. Safinamide's mechanism of action includes potent, selective, and reversible inhibition of MAO-B, without affecting MAO-A and dopamine uptake, thus enhancing dopaminergic function and inhibiting glutamate release. It reduces the degradation of dopamine, thus showing potential activity in the treatment of RLS. Similarly, Serina's drug SER-214 involves a water-soluble polymer poly (2-alkyloxazoline)-based drug delivery technology. The drug can be connected to the polymer and delivered to target specific receptors.
According to the report, the unknown etiology of the disease prevents the introduction of drugs that treat the exact cause of the disease. The currently marketed drugs offer only symptomatic relief. In addition, adverse effects such as nervous system disorders, which include sedation, headache, and dizziness; gastrointestinal disorders such as nausea, dry mouth, and flatulence; psychiatric disorders, including depression and decreased libido; metabolism and nutritional disorders, including weight gain and increased appetite; ear and labyrinth disorders resembling vertigo; and other general disorders such as fatigue, irritability, and peripheral edema are associated with the use of these drugs. This creates unmet needs in the market. Any drug that can provide a complete cure with minimal side effects would experience widespread adoption in the market.
Further, the report states that the unknown disease etiology is one of the major challenges for vendors in the market.
Key vendors
- Boehringer Ingelheim
- GlaxoSmithKline
- UCB
- XenoPort
Other prominent vendors
- Alexza Pharmaceuticals
- Astellas Pharma
- Axxonis Pharma
- Bayer Healthcare
- Impax Pharmaceuticals
- Luitpold Pharmaceuticals
- Merz Pharmaceuticals
- Mundipharma
- Newron Pharmaceuticals
- Serina Therapeutics
- Teva Neuroscience
Key Topics Covered:
- Executive Summary
- List of Abbreviations
- Scope of the Report
- Market Research Methodology
- Product Profiles
- Introduction
- Disease Overview
- Pipeline Analysis
- Commercial Opportunities
- Key Brand Analysis
- Market Landscape
- Market Segmentation by Class of Drugs
- Geographical Segmentation
- Buying Criteria
- Market Growth Drivers
- Drivers and their Impact
- Market Challenges
- Impact of Drivers and Challenges
- Market Trends
- Trends and their Impact
- Vendor Landscape
- Key Vendor Analysis
For more information visit http://www.researchandmarkets.com/research/646k6k/global_restless
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets
Share this article